Genmab A/S
Kalvebod Brygge 43
DK-1560 Copenhagen V
Denmark
Tel. +45 7020 2728
www.genmab.com
CVR no. 2102 3884

February 28, 2019

Dear Shareholder,

Please find enclosed an invitation to attend Genmab A/S' Annual General Meeting to be held on

Friday, March 29, 2019 at 11:00 AM CET at
Copenhagen Marriott Hotel
Kalvebod Brygge 5
DK-1560 Copenhagen V
Denmark

The Annual General Meeting gives you an opportunity to hear about the many achievements made by Genmab in 2018.

This was the year where we progressed a number of exciting projects in our pipeline. Building on the promising data we saw for tisotumab vedotin in cervical cancer in 2017, last year we moved this program forward together with our collaboration partner Seattle Genetics. We treated the first patients in a Phase II study of tisotumab vedotin in recurrent and/or metastatic cervical cancer. If the data from this study is supportive, we could potentially file regulatory applications to bring tisotumab vedotin to the market – making this product the first that Genmab could market with its own commercial team. In addition to this potential registration study we added three new studies in various solid tumors to the tisotumab vedotin development program during 2018.

We also made very significant progress with other early stage proprietary clinical programs last year. The enapotamab vedotin study in solid tumors was expanded in several tumor types. We also treated the first patients with two products created with our proprietary antibody technologies: The HexaBody®-DR5/DR5 program is in the first ever clinical trial of a product made with our enhanced potency HexaBody technology platform and Genmab's first fully owned DuoBody® bispecific antibody product, DuoBody-CD3xCD20, is in a Phase I/II study in B-cell malignancies. In order to ensure we continue to bring new promising treatments forward, we also invested in our innovative pre-clinical pipeline and aim to bring at least three new programs into clinical development during 2019.

DARZALEX® also continued its strong trajectory, with over 60,000 patients with multiple myeloma treated by the end of 2018. Due to new approvals for DARZALEX a growing number of patients with this type of cancer now have access to this first-in-class drug. We also look forward to further label expansions following the positive topline data reported last year from two key Phase III studies of DARZALEX in combination with other standard therapies for frontline multiple myeloma.

2018 was a strong year for Genmab where we continued to work hard on moving our pipeline forward and I look forward to further describing our progress at the Annual General Meeting. However, if you are unable to attend, I encourage you to return the enclosed proxy, or to vote by post. I would like to take this opportunity to thank you for your continued support.

Sincerely yours,

Jan van de Winkel, Ph.D.
President & Chief Executive Officer